-
JAMA Network Open丨Dr. Fanpu Ji’s Team: Trends and Projections of Hepatocellular Carcinoma Mortality Rates in the U.S.
Background and Key Findings Globally, the burden of liver cancer is significant. In 2020, it was the sixth most common cancer and the third leading cause of cancer deaths worldwide.…
-
From Risk-Based to Disease-Oriented Treatment: Response, Remission, and Cure in the MRD Era of Colorectal Cancer
Traditionally, decisions regarding adjuvant chemotherapy after colorectal cancer surgery have been based on a patient’s risk of recurrence, determined by TNM staging and histopathological features. However, emerging evidence suggests that these guidelines, in place since 2004, may not be the most effective approach and could be inadequate. In fact, surgery alone has already achieved high…
-
Dr. Petrv Tsarkov:Clinical Controversies and Considerations in Lymphadenectomy for Colorectal Cancer
Lateral lymph node (LLN) metastasis in locally advanced rectal cancer is associated with patient prognosis. However, the clinical significance of lateral lymph node dissection (LLND) has always been a matter of debate in the academic community. We have invited Dr. Petrv Tsarkov from Chechenov State Medical University in Moscow to share his insights and thoughts…
-
Dr. Ashwin Somasundaram：How Should Adjuvant Therapy Be Decided for High-Risk MSI-H Stage II Colorectal Cancer?
The decision on whether high-risk MSI-H (microsatellite instability-high) stage II colorectal cancer patients should receive adjuvant therapy remains controversial. Dr. Ashwin Somasundaram, a medical professor at the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, shares his insights on this complex issue.
-
ESMO ASIA 2024 | Dr. Guohai Shi: Advances in Targeted and Immunotherapy for Renal Cell Carcinoma
Renal cell carcinoma (RCC) is one of the three major tumors of the urinary system. In recent years, the development of targeted and immunotherapy drugs—particularly the success of several large-scale Phase III trials of combination therapies—has ushered in a new era of targeted and immunotherapy combinations for advanced RCC. At this year’s ESMO ASIA Congress,…
-
Dr. Huiping Li: Advances in Precision Treatment for BRCA-Mutated Breast Cancer | 2024 Straits Breast Cancer Forum
Breast cancer is the most common malignancy among women worldwide, with approximately 5% to 10% of patients carrying BRCA gene mutations. These patients often present with more advanced disease, face a higher risk of recurrence, and have poorer prognoses. For patients with germline BRCA-mutated (gBRCA) triple-negative breast cancer (TNBC), platinum-based chemotherapy remains the standard treatment…
-
Dr. Huiping Li: Advances in Precision Treatment for BRCA-Mutated Breast Cancer | 2024 Straits Breast Cancer Forum
Breast cancer is the most common malignancy among women worldwide, with approximately 5% to 10% of patients carrying BRCA gene mutations. These patients often present with more advanced disease, face a higher risk of recurrence, and have poorer prognoses. For patients with germline BRCA-mutated (gBRCA) triple-negative breast cancer (TNBC), platinum-based chemotherapy remains the standard treatment…
-
SABCS 2024 | Dr. Jia Wang: Survival Data from Different Chemotherapy Regimens in the WSG-ADAPT HR+/HER2- Study Released
At the highly anticipated 2024 San Antonio Breast Cancer Symposium (SABCS), numerous groundbreaking studies in breast cancer treatment were unveiled. Among them, the Working Group for Gynecological Oncology (WSG) presented long-term survival data from the WSG ADAPT-HR+/HER2- early breast cancer chemotherapy cohort (Abstract No.: GS3-04). This study integrates clinical pathology, genomic testing, and endocrine therapy…
Connecting Medical Expertise through Media